Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
Revisit the OncLive On Air Episodes From February 2024
SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy
State of the Science Summit - Hematologic Malignancies: Chaired by Catherine E. Lai, MD, MPH
Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology
Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer